In a genome-wide and whole transcriptome sequencing on 6 ICC samples with FGFR2 translocations in 3/6 (50%) patients, two out of three patients responded to FGFR2 inhibitors [30]. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.